Pirfenidone prevents rat esophageal stricture formation

Orozco-Pérez, Jaime; Aguirre-Jáuregui, Oscar Miguel; Salazar-Montes, Adriana; Sobrevilla-Navarro, Ana Alondra; Lucano-Landeros, Martha Silvia; Armendáriz‐Borunda, Juan

doi:10.1016/j.jss.2014.11.009

Cited by 17 publications

(20 citation statements)

References 24 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Orozco‐Perez et al conducted a study using an esophageal stricture model and demonstrated that the fibrosis was prevented in the pirfenidone group by the suppressed expression of the profibrotic genes, resulting in the development of narrowness in the esophagus lumen to a lesser degree.…”

Section: Discussionmentioning

confidence: 99%

“…After it was discovered that pirfenidone had antifibrotic effects on the pulmonary fibrosis induced by bleomycin in hamsters, it was studied in several models of fibrotic diseases, demonstrating its antifibrotic, anti‐inflammatory, and antioxidant effects …”

Section: Discussionmentioning

confidence: 99%

“…24,25 After it was discovered that pirfenidone had antifibrotic effects on the pulmonary fibrosis induced by bleomycin in hamsters, it was studied in several models of fibrotic diseases, demonstrating its antifibrotic, antiinflammatory, and antioxidant effects. 10 Liu et al 26 conducted a study on lung transplantation on two different species of rats and demonstrated that 0.5% pirfenidone administered in the food inhibited peribronchial and interstitial fibrosis. Zhou et al 12 studied a heterotopic tracheal allograft model on murines and demonstrated that the degrees of inflammation, intraluminal degranulation, and fibrosis were reduced in the transplanted tissues collected from the murine subjects, which were administered 0.5% pirfenidone in the food for prophylactic purposes.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prevention of tracheal stenosis with pirfenidone after tracheotomy: An experimental study

Türkmen

Pata

2018

The Laryngoscope

View full text Add to dashboard Cite

Objectives In this study, pirfenidone's role about reducing tracheal stenosis by suppressing fibrosis and inflammation was examined. Methods Tracheotomy was performed on 14 rats, and their cannulas were fixed to tracheotomy area by stoma suture. Two working groups were established. Rats in the first group were given 15 mg/kg/day (1 mL pirfenidone solution) pirfenidone intraperitoneally for 10 days. In the second group as a control group, 1 mL saline solution was applied intraperitoneally. Ten days later, rats were decanulated and kept alive for 3 more weeks. Anesthetized rats were sacrificed on day 30. All rat tracheas were resected between the first and seventh rings. Epithelial damage, inflammation, and fibrosis were determined histopathologically; diameters of intratracheal lumen and their mucosal thickness parameters were determined histomorphometrically; and TGFβ‐1 (the growth factor beta), TNFα (tumor necrosis factor alpha), and IL‐1β (Interleukin‐1 beta) values were determined immunohistochemically. Results According to the parameters of the control group, fibrosis; diameters of intratracheal lumen; and values of TGFβ‐1, TNFα, and IL‐1β were found to be statistically significant. Conclusion In our study, it was found that pirfenidone reduces fibrosis and narrowing of intratracheal lumen diameter significantly. Level of Evidence NA Laryngoscope, 129:E178–E186, 2019

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of tracheal stenosis with pirfenidone after tracheotomy: An experimental study

Türkmen

Pata

2018

The Laryngoscope

View full text Add to dashboard Cite

show abstract

“…This response was essentially absent in PFD-dosed mice after sham surgery, consistent with an antifibrotic effect of PFD on the soft tissue wounds. 58,59 PFD blocking of bone pitting and erosion near the injury site in both genotypes ( Fig. 1B vs. D) might be explained by the PFD-stimulated expression of genes which have been implicated in bone turnover, such as Irf1 48 and Nfkb2.…”

Section: The Relationship Between Has1 Fibrosis and Bone Metabolismmentioning

confidence: 93%

Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury

Chan

Luo

et al. 2017

Journal Orthopaedic Research

View full text Add to dashboard Cite

Pirfenidone is an anti-inflammatory and anti-fibrotic drug that has shown efficacy in lung and kidney fibrosis. Because inflammation and fibrosis have been linked to the progression of osteoarthritis, we investigated the effects of oral Pirfenidone in a mouse model of cartilage injury, which results in chronic inflammation and joint-wide fibrosis in mice that lack hyaluronan synthase 1 (Has1 ) in comparison to wild-type. Femoral cartilage was surgically injured in wild-type and Has1 mice, and Pirfenidone was administered in food starting after 3 days. At 4 weeks, Pirfenidone reduced the appearance, on micro-computed tomography, of pitting in subchondral bone at, and cortical bone surrounding, the site of cartilage injury. This corresponded with a reduction in fibrotic tissue deposits as observed with gross joint surface photography. Pirfenidone resulted in significant recovery of trabecular bone parameters affected by joint injury in Has1 mice, although the effect in wild-type was less pronounced. Pirfenidone also increased Safranin-O staining of growth plate cartilage after cartilage injury and sham operation in both genotypes. Taken together with the expression of selected extracellular matrix, inflammation, and fibrosis genes, these results indicate that Pirfenidone may confer chondrogenic and bone-protective effects, although the well-known anti-fibrotic effects of Pirfenidone may occur earlier in the wound-healing response than the time point examined in this study. Further investigations to identify the specific cell populations in the joint and signaling pathways that are responsive to Pirfenidone are warranted, as Pirfenidone and other anti-fibrotic drugs may encourage tissue repair and prevent progression of post-traumatic osteoarthritis. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:365-376, 2018.

show abstract

“…[ 5 6 7 8 ] The drug is now being studied in animal models for non-IPF ILDs and non-pulmonary fibrotic conditions. [ 9 10 11 12 ] It has also been evaluated in humans with non-pulmonary fibrosing disorders. [ 13 14 ] Its efficacy in SSc-ILD has been previously reported, although the study has included only five patients.…”

mentioning

confidence: 99%

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?

2015

View full text Add to dashboard Cite

Pirfenidone prevents rat esophageal stricture formation

Cited by 17 publications

References 24 publications

Prevention of tracheal stenosis with pirfenidone after tracheotomy: An experimental study

Prevention of tracheal stenosis with pirfenidone after tracheotomy: An experimental study

Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?

Contact Info

Product

Resources

About